gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CERSHealthcareSurgical Instruments

Cerus Corp (CERS)

$2.42+3.21%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.42▲ 66.55% in range
Nov 4, 2025Low $1.41 · High $3.28Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Cerus closed at $2.42 on Nov 4, up 3.21%, 26.4% below its 52-week closing high. Volume of 2.5M shares was 1.26× its 20-day average (above normal).

Split-adjusted performance: +3.2% over one month, -6.8% over six months, +58.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $64.02M, up 6.3% from a year earlier, with a net margin of -0.9%.

Short interest was 16.6M shares at the Oct 15 settlement, down 5.4% from the prior report (8.6% of float, 9.4 days to cover).

Market cap$486.7M201.5M shares
Revenue · quarter$64.0M+6.3% YoY
Diluted EPS$0.00—
P/E · TTM—P/S 1.9×
Net margin-0.9%Gross 57.1%
Dividend yieldNone
52-week range1.41 – 3.28−26.4% from high
Volume2.5M1.26× 20-day avg
Volatility · 60d44.7%Annualised
Short % of float8.6%9.4 days to cover
Net cash-$6.2MCash $57.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.2%1M +3.2%3M +4.1%6M −6.8%YTD +17.2%1Y +58.9%3Y +84.4%5Y −61.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum48
Revenue growth44
Net margin59
Value (low P/E)—
Size60

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short16.6M−5.4% vs prior
Days to cover9.4Settled Oct 15
% of float8.6%
Short vol. 10d50.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CERSCerus$2.42+3.21%−6.8%+6.3%−0.9%—$486.7M
RCELAvita Medical$16.32+6.46%+269.2%+17.8%−35.3%—$504.7MCompare
MDXGMiMedx Group$3.20−1.54%−12.6%−45.2%−13.9%—$467.0MCompare
DCTHDelcath Systems$14.82+2.92%+31.6%+20.6%9.2%966.6$514.2MCompare
ANGOAngioDynamics$12.25+4.43%+10.9%+6.9%−8.8%—$515.2MCompare
NPCENeuropace$13.34+8.37%−26.4%+17.1%−27.2%—$457.9MCompare
SSIISS Innovations International$2.27−2.58%−44.2%+39.4%−19.1%—$455.1MCompare
SGHTSight Sciences$9.68+2.76%+125.1%+19.5%−19.0%—$533.3MCompare
CARLCarlsmed$16.09+11.74%+63.5%—−55.5%—$439.3MCompare

News about Cerus

All news →
Cerus: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 1d ago▲ Positive

Quick answers

What does Cerus do?
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites.
What is CERS's market cap?
$486.68M, based on the Nov 4 close of $2.42.
Does Cerus pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CERS is sold short?
16.6M shares, 8.6% of float, as of Oct 15, 2026.
What sector is CERS in?
Healthcare, in the Surgical Instruments industry.

About Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

HQ: Concord, CA345 employeesListed Jan 31, 1997cerus.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology